Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments

  • Technology appraisal guidance
  • TA930
  • Published: 
The appraisal committee meeting scheduled for 2 August 2023 is now expected to take place on 6 September 2023.